Condition: Cutaneous Squamous Cell Carcinoma · Skin Cancers - Squamous Cell Carcinoma · Sponsor: Falo, Louis, MD
The purpose of this study is to test a new method of experimental treatment for cutaneous squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have dozens of very small micro-needles loaded with extremely low doses of doxorubicin, a chemotherapy agent. The overall goal of this study is to test the safety and effectiveness of these patches. The investigators have established the highest tolerated dose at 50 micrograms in a previous study for a different type of cancer that affects the skin. The investigators will thoroughly evaluate the skin where the patches are applied.
This description comes directly from the study's public registry record.
Charity L Ruhl, LPN · 1-412-647-2013 · ruhlcl@upmc.edu
Nicolena Verardi · 1-412-864-3682 · verardin3@upmc.edu
Always discuss trial participation with your own doctor first.
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05377905